DALLAS--(BUSINESS WIRE)--MD Buyline offers the complimentary report Reimbursement Opportunities and Challenges in 2014 to healthcare providers, sharing opportunities, challenges and changes that impact inpatient and outpatient reimbursement rates.
The white paper addresses the transition from charge-based payments to refined reimbursement, including severity-adjusted Diagnostic Related Groups (DRGs) and cost-based Ambulatory Payment Classification (APC) codes. Intended to improve the value and quality of care, the CMS-mandated transition puts pressure on healthcare providers to tie reimbursement to quality and outcomes, as well as initiate value-based purchasing processes.
In the report, MD Buyline’s clinical experts provide insight into:
- Major changes to the Inpatient Prospective Payment System (IPPS) and Outpatient Prospective Payment System (OPPS)
- How to make combined therapies and diagnostic practices more efficient for composite APCs
- How to optimize savings to combat package pricing
- Opportunities and challenges for cardiology, imaging, radiation therapy, proton beam therapy, nuclear medicine/molecular imaging, surgery and laboratory
“Reimbursement Opportunities and Challenges in 2014 is designed to identify growth areas for hospitals looking to maximize CMS-reimbursed technologies and services. We’re trying to help healthcare providers improve their bottom line and provide more value to patients. There are direct and indirect ways to accomplish this, and that’s why MD Buyline’s analysts work one-on-one with our members to customize the best purchasing route for their needs and goals,” said Mr. James Laskaris, emerging technology analyst with MD Buyline.
MD Buyline’s clinical analysts work with healthcare providers across the nation to target the right technology for their hospital’s unique needs. Focusing on capital, IT and supply purchases CMS incentivizes aids hospitals with tight budgets and accomplishes value-based purchasing.
About MD Buyline
Healthcare providers recognize MD Buyline as the leading provider of evidence-based information and research. By creating transparency and fostering consultative relationships, MD Buyline has partnered with providers for more than three decades to identify cost reduction opportunities for purchased services, consumables, capital and IT. Providers rely on MD Buyline’s data and clinical analysts for financial and clinical insight to reach long- and short-term goals. For more information, please visit www.mdbuyline.com, and follow MD Buyline on Twitter, @MDBuyline.